Volume 5 Issue 1
Jun.  2021
Turn off MathJax
Article Contents
Article Navigation >  Blood&Genomics  > 2021  >  5(1): 41-47
Lei Liu, Wanbing Liu, Yan Liu, Guomei Kou, Yaqiong Zheng, Liping Cai, Shengdian Wang, Shangen Zheng. Comparative analysis of antibody responses to SARS-CoV-2 in various populations[J]. Blood&Genomics, 2021, 5(1): 41-47. doi: 10.46701/BG.2021012021102
Citation: Lei Liu, Wanbing Liu, Yan Liu, Guomei Kou, Yaqiong Zheng, Liping Cai, Shengdian Wang, Shangen Zheng. Comparative analysis of antibody responses to SARS-CoV-2 in various populations[J]. Blood&Genomics, 2021, 5(1): 41-47. doi: 10.46701/BG.2021012021102
shu

Comparative analysis of antibody responses to SARS-CoV-2 in various populations

doi: 10.46701/BG.2021012021102
  • 1.

    Department of Transfusion Medicine, General Hospital of Central Theater Command of the PLA, Wuhan, Hubei 430070, China

  • 2.

    Wuhan School of Clinical Medicine, Southern Medical University, Wuhan, Hubei 430070, China

  • 3.

    CAS Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China

More Information
  • Corresponding author: Shengdian Wang, CAS Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, 15 Datun Rd, Beijing 100101, China. E-mail: sdwang@ibp.ac.cn; Shangen Zheng, Department of Transfusion Medicine, General Hospital of Central Theater Command of the PLA, 627 Wuluo Rd, Wuhan, Hubei 430070, China. E-mail: sxkzsg@sina.com.
  • Received Date: 2021-01-20
  • Accepted Date: 2021-06-01
  • Rev Recd Date: 2021-04-20
  • Publish Date: 2021-06-01
    Abstract
  • This paper aimed to analyze antibody responses to SARS-CoV-2 in various populations. Two hundred and six COVID-19 patients, 46 convalescent patients, and 270 healthy population were enrolled. Antibodies against nucleocapsid protein (N) and spike protein's receptor-binding domain (RBD), and neutralizing antibody were detected. The results demonstrated both anti-N and anti-RBD antibodies could be detected in about 80% of COVID-19 patients and 90% of convalescent patients, while no antibodies could be detected in some convalescents and patients even after 14 days post-onset of symptoms. The level of anti-RBD antibody strongly correlated with the neutralizing activity of sera from these two cohorts. The titer of neutralizing antibody was lower in convalescents than that in active COVID-19 patients. In addition, the titer of neutralizing antibody was less than 1:80 in none of the severe COVID-19 patients, 18.8% in non-severe COVID-19 patients, and 32.6% in convalescents. The study suggests that the level of anti-RBD antibody is closely related to neutralization activity in COVID-19 patients and convalescents. Some SARS-CoV-2-infected cases trigger a weak antiviral immune response, and the level of neutralizing antibody may have a faster decay rate.

     

    • △These authors contributed equally to this work.
    FullText(HTML)
  • loading
    • References(20)
  • [1]
    Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19[J]. Nat Med, 2020, 26(6): 845−848. doi: 10.1038/s41591-020-0897-1
    [2]
    Liu L, Liu WB, Zheng YQ, et al. A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients[J]. Microbes Infect, 2020, 22(4-5): 206−211. doi: 10.1016/j.micinf.2020.05.008
    [3]
    Petherick A. Developing antibody tests for SARS-CoV-2[J]. Lancet, 2020, 395(10230): 1101−1102. doi: 10.1016/S0140-6736(20)30788-1
    [4]
    Zhao JJ, Yuan Q, Wang HY, et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019[J]. Clin Infect Dis, 2020, 71(16): 2027−2034. doi: 10.1093/cid/ciaa344
    [5]
    Okba NMA, Widjaja I, Li WT, et al. Serologic detection of middle east respiratory syndrome coronavirus functional antibodies[J]. Emerg Infect Dis, 2020, 26(5): 1024−1027. doi: 10.3201/eid2605.190921
    [6]
    Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections[J]. Nat Med, 2020, 26(8): 1200−1204. doi: 10.1038/s41591-020-0965-6
    [7]
    Zhang YC, Shen H, Wang XN, et al. Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients[J]. Emerg Microbes Infect, 2020, 9(1): 833−836. doi: 10.1080/22221751.2020.1756699
    [8]
    McIntosh K, Kapikian AZ, Hardison KA, et al. Antigenic relationships among the coronaviruses of man and between human and animal coronaviruses[J]. J Immunol, 1969, 102(5): 1109-1118.
    [9]
    Walls AC, Park YJ, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein[J]. Cell, 2020, 181(2): 281−292. e6. doi: 10.1016/j.cell.2020.02.058
    [10]
    Shen CG, Wang ZQ, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma[J]. JAMA, 2020, 323(16): 1582−1589. doi: 10.1001/jama.2020.4783
    [11]
    Salazar E, Perez KK, Ashraf M, et al. Treatment of coronavirus disease 2019 (COVID-19) patients with convalescent plasma[J]. Am J Pathol, 2020, 190(8): 1680−1690. doi: 10.1016/j.ajpath.2020.05.014
    [12]
    Seydoux E, Homad LJ, MacCamy AJ, et al. Analysis of a SARS-CoV-2-infected individual reveals development of potent neutralizing antibodies with limited somatic mutation[J]. Immunity, 2020, 53(1): 98−105. e5. doi: 10.1016/j.immuni.2020.06.001
    [13]
    Cao YL, Su B, Guo XH, et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells[J]. Cell, 2020, 182(1): 73−84. e16. doi: 10.1016/j.cell.2020.05.025
    [14]
    Amanat F, Stadlbauer D, Strohmeier S, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans[J]. Nat Med, 2020, 26(7): 1033−1036. doi: 10.1038/s41591-020-0913-5
    [15]
    Premkumar L, Segovia-Chumbez B, Jadi R, et al. The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients[J]. Sci Immunol, 2020, 5(48): eabc8413. doi: 10.1126/sciimmunol.abc8413
    [16]
    Gao Q, Bao LL, Mao HY, et al. Development of an inactivated vaccine candidate for SARS-CoV-2[J]. Science, 2020, 369(6499): 77−81. doi: 10.1126/science.abc1932
    [17]
    Zhou F, Yu T, Du RH, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study[J]. Lancet, 2020, 395(10229): 1054−1062. doi: 10.1016/S0140-6736(20)30566-3
    [18]
    Wang XL, Guo XH, Xin QQ, et al. Neutralizing antibody responses to severe acute respiratory syndrome coronavirus 2 in coronavirus disease 2019 inpatients and convalescent patients[J]. Clin Infect Dis, 2020, 71(10): 2688−2694. doi: 10.1093/cid/ciaa721
    [19]
    Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals[J]. Nature, 2020, 584(7821): 437−442. doi: 10.1038/s41586-020-2456-9
    [20]
    Xu X, Sun J, Nie S, et al. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China[J]. Nat Med, 2020, 26(8): 1193−1195. doi: 10.1038/s41591-020-0949-6
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (31) PDF downloads(1) Cited by()
    Proportional views
    Related

    Copyright © Blood and Genomics苏公网安备 32028102000501号苏ICP备14047883号-3

    Address：Rooms 1318-19, Hollywood Plaza, 610 Nathan Road, Mongkok, Kowloon, HongKong

    E-mail：editorial_office@apjbg.com

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return